News

Praluent is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor indicated as adjunct to diet and maximally tolerated statin therapy to treat adults with heterozygous familial hypercholesterolemia (HeFH)

Scheduled for completion in the first quarter of 2018, the building is planned to begin operations in early 2019. Expected to cost approximately 70 million euro ($79 million),

IPF results from the build-up of scar tissue (fibrosis) in the lungs, which prevents normal uptake of oxygen. Scar tissue is comprised of collagen fibres which, when excessively

Epidarex Capital, EMBL Ventures and Gimv participated together with Evotec in the EUR 14 m ($ 15.75 m) Series A round of Topas Therapeutics GmbH. Evotec will remain

Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer. "Over the last

Taltz, which is administered as an injection, is indicated for patients who are candidates for systemic therapy or phototherapy. It is a humanized IgG4 monoclonal antibody that selectively

Enstilar is an alcohol-free foam formulation for the topical treatment for psoriasis vulgaris. LEO Pharma president and CEO Gitte Aabo said: "The scientific approval of Enstilar is exciting

The novel compounds, developed in the laboratory of Harvard scientist Matthew Shair, Ph.D., offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription. Acute myeloid leukemia

ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of